P01283753A09
Among_II the_DD four_MC non-responders_NNS who_PNR were_VBD NS_NN positive_JJ during_II IFN_NN ,_, three_MC were_VBD NC_NN positive_JJ before_II IFN_NN ._.
P01309200A14
Most_PND of_II these_PND appear_VVB to_TO represent_VVI false-positive_JJ results_NNS because_CS HCV_NN RNA_NN is_VBZ usually_RR absent_JJ from_II the_DD serum_NN ._.
P01315339A03
The_DD introduction_NN of_II new_JJ epitopes_NNS ,_, particularly_RR a_DD core_NN protein_NN ,_, C22_NN (_( second-generation_NN tests_NNS )_) ,_, seems_VVZ to_TO increase_VVI the_DD sensitivity_NN of_II anti-HCV_NN detection_NN ._.
P01325035A08
Among_II the_DD organ_NN recipients_NNS ,_, the_DD prevalence_NN of_II HCV_NN RNA_NN increased_VVD after_II transplantation_NN :_: 7_MC of_II 26_MC patients_NNS (_( 27_MC percent_NN )_) had_VHD positive_JJ samples_NNS before_II transplantation_NN ,_, as_CS compared_VVN with_II 23_MC of_II 24_MC patients_NNS (_( 96_MC percent_NN )_) after_II transplantation_NN (_( P_NN less_RR than_CSN 0.001_MC )_) ._.
P01327328A04
Of_II these_DD HCV_NN antibody-positive_JJ patients_NNS 89_MC were_VBD tested_VVN for_II a_DD second_JJ time_NN ._.
P01327684A01
We_PN evaluated_VVD the_DD prevalence_NN of_II hepatitis_NN C_NN virus_NN (_( HCV_NN )_) RNA_NN and_CC antibody_NN (_( anti-HCVcore_NN )_) to_II the_DD putative_JJ HCV_NN core_NN protein_NN in_II Japanese_JJ patients_NNS with_II chronic_JJ liver_NN disease_NN ._.
P01331274A03
We_PN studied_VVD the_DD percentage_NN of_II pregnant_JJ women_NNS in_II our_PNG hospital_NN with_II antibodies_NNS to_II HCV_NN ,_, and_CC tried_VVD to_TO compare_VVI the_DD C100-3_NN antibodies_NNS with_II PHA_NN results_NNS in_II pregnant_JJ women_NNS ._.
P01331309A04
In_II contrast_NN ,_, antibody_NN reactivity_NN persisted_VVD in_II 7_MC of_II 8_MC patients_NNS with_II chronic_JJ HCV_NN infection_NN who_PNR could_VM be_VBB followed_VVN until_II 1990_MC ._.
P01332561A10
Of_II the_DD 23_MC mothers_NNS ,_, 21_MC (_( 91_MC %_SYM ;_: Cl_NN ,_, 72_MC %_SYM to_II 99_MC %_SYM )_) had_VHD a_DD reactive_JJ RIBA_NN ;_: one_MC woman_NN had_VHD an_DD indeterminate_JJ RIBA_NN and_CC was_VBD positive_JJ for_II HCV_NN RNA_NN by_II PCR_NN ._.
P01332562A07
Two_MC children_NNS had_VHD long-lasting_VVGJ alanine_NN aminotransferase_NN (_( ALT_NN )_) elevations_NNS ,_, and_CC one_MC of_II them_PN became_VVD HCV_NN RNA_NN positive_JJ ._.
P01378484A11
A_DD wide_JJ spectrum_NN of_II viral_JJ and_CC antibody_NN patterns_NNS in_II anti-HCV_NN c100-3_NN positive_JJ sera_NNS was_VBD observed_VVN in_II this_DD urban_JJ population_NN and_CC persisted_VVD for_II at_RR+ least_RR 6_MC years_NNS ._.
P01378811A06
Elevated_VVNJ alanine_NN aminotransferase_NN levels_NNS were_VBD present_JJ in_II 12.5_MC %_SYM of_II the_DD dialysis_NN patients_NNS ,_, 77_MC %_SYM of_II whom_PNR were_VBD also_RR anti-HCV_NN positive_JJ ._.
P01656140A12
However_RR ,_, not_RR all_DD anti-HCV_NN positive_JJ patients_NNS had_VHD HCV_NN positive_JJ hepatitis_NN ._.
P01667711A02
In_II these_DD subjects_NNS we_PN recorded_VVD some_DD clinical_JJ and_CC anamnestic_JJ data_NNS (_( history_NN of_II blood_NN transfusion_NN ,_, risk_NN factors_NNS of_II liver_NN disease_NN ,_, therapy_NN )_) and_CC determined_VVD ,_, besides_II a_DD few_JJ routine_JJ laboratory_NN parameters_NNS including_VVG rheumatoid_JJ factor_NN (_( RF_NN )_) ,_, AST_NN and_CC ALT_NN ,_, the_DD anti-HCV_NN serology_NN using_VVG the_DD 1st_JJ (_( EIA_NN ,_, Ortho_NN and_CC Abbott_NN ;_: Neutralization_NN test_NN ,_, Abbott_NN ;_: RIBA_NN ,_, Chiron-Ortho_NN )_) and_CC the_DD 2nd_JJ generation_NN tests_NNS (_( EIA_NN ,_, Ortho_NN ;_: RIBA_NN ,_, Chiron-Ortho_NN )_) ._.
P01724983A10
Of_II these_DD 22_MC sera_NNS plus_CC 1_MC further_RR with_II ELISA_NN OD_NN just_RR below_II cutoff_NN ,_, 8_MC were_VBD positive_JJ by_II the_DD "_`` neutralization_NN assay_NN ,_, "_'' (_( Abbott_NN Laboratories_NNS ,_, North_NN Chicago_NNP ,_, IL_NNP ,_, USA_NNP )_) and_CC 6_MC of_II these_PND ,_, including_VVG the_DD borderline_NN serum_NN ,_, were_VBD PCR_NN positive_JJ ._.
P02174157A04
HCV_NN is_VBZ a_DD small_JJ RNA_NN virus_NN with_II a_DD lipid_NN capsid_NN ,_, and_CC it_PN might_VM be_VBB indirectly_RR related_VVN to_II the_DD flaviviruses_NNS ._.
P07489343A06
Therefore_RR ,_, post-treatment_NN hepatitis_NN C_NN exacerbations_NNS show_VVB the_DD same_JJ sequence_NN of_II events_NNS seen_VVN as_CSN in_II hepatitis_NN B_NN exacerbations_NNS (_( increases_NNS of_II viraemia_NN followed_VVN by_II those_PND of_II ALT_NN and_CC IgM_NN anti-'core_NN '_'' )_) ._.
P07505079A08
Of_II the_DD 2_MC HCV-RNA_NN negative_JJ patients_NNS ,_, one_MC had_VHD been_VBN PCR_NN positive_JJ before_II interferon_NN therapy_NN ._.
P07508489A03
Results_NNS showed_VVD that_CST on_II entry_NN (_( i_MC )_) sera_NNS of_II 83_MC out_II+ of_II 272_MC members_NNS of_II the_DD cohort_NN were_VBD positive_JJ by_II the_DD HCV_NN 1st_JJ generation_NN EIA_NN (_( 30.5_MC %_SYM )_) ;_: 70_MC were_VBD confirmed_VVN by_II the_DD neutralization_NN test_NN (_( 84.3_MC %_SYM )_) ;_: (_( ii_MC )_) 115_MC of_II the_DD cohort_NN were_VBD reactive_JJ with_II the_DD 2nd_JJ generation_NN HCV_NN EIA_NN (_( 41.3_MC %_SYM )_) ;_: (_( iii_MC )_) with_II the_DD dot-blot_NN immunoassay_NN 99_MC (_( 86.1_MC %_SYM )_) of_II the_DD cohort_NN were_VBD confirmed_VVN and_CC 16_MC remained_VVD indeterminate_JJ ._.
P07508972A04
Of_II the_DD 15_MC anti-HCV-positive_JJ donors_NNS with_II normal_JJ ALT_NN ,_, only_RR five_MC (_( 33_MC %_SYM )_) were_VBD confirmed_VVN to_TO be_VBI positive_JJ by_II second-generation_NN RIBA_NN ,_, six_MC (_( 40_MC %_SYM )_) were_VBD indeterminate_JJ ,_, while_CS four_MC (_( 27_MC %_SYM )_) were_VBD RIBA_NN negative_JJ ._.
P07519631A05
Serum_NN transaminases_NNS were_VBD increased_VVN in_II 46_MC cases_NNS (_( 77_MC %_SYM )_) ,_, and_CC HCV_NN RNA_NN was_VBD detected_VVN by_II PCR_NN in_II 50_MC cases_NNS (_( 83_MC %_SYM )_) ._.
P07519818A02
METHODS_NNS :_: Sera_NNS from_II 46_MC patients_NNS were_VBD compared_VVN before_II and_CC after_II liver_NN transplantation_NN for_II markers_NNS of_II HCV_NN infection_NN ._.
P07519896A05
Although_CS the_DD Nantong_NNP area_NN is_VBZ a_DD high_JJ risk_NN region_NN for_II PHC_NN ,_, these_DD data_NNS suggest_VVB that_CST HCV_NN infection_NN is_VBZ not_RR an_DD important_JJ aetiological_JJ factor_NN for_II PHC_NN in_II this_DD area_NN ._.
P07523308A04
Anti-HCV_NN was_VBD determined_VVN by_II means_NNS of_II ELISA_NN II_MC and_CC was_VBD confirmed_VVN by_II RIBA_NN II_MC ._.
P07523676A07
Nine_MC organs_NNS from_II four_MC RIBA-positive_JJ donors_NNS were_VBD transplanted_VVN into_II eight_MC recipients_NNS of_II whom_PNR four_MC became_VVD anti-HCV_NN and_CC PCR_NN positive_JJ after_II transplantation_NN ._.
P07526275A02
In_II order_NN to_TO assess_VVI prevalence_NN and_CC risk_NN factors_NNS for_II HCV_NN infection_NN in_II CRF_NN patients_NNS on_II conservative_JJ therapy_NN we_PN tested_VVD ,_, by_II second-generation_NN assays_NNS such_II+ as_II Ortho_NN 2_MC and_CC 4-RIBA_NN ,_, 221_MC predialysis_NN CRF_NN patients_NNS attending_VVG our_PNG Department_NN ._.
P07529251A03
This_DD method_NN was_VBD compared_VVN with_II a_DD commercially_RR available_JJ second-generation_NN enzyme_NN immunoassay_NN (_( EIA_NN )_) which_PNR employed_VVD synthetic_JJ peptides_NNS corresponding_VVG to_II highly_RR antigenic_JJ segments_NNS of_II both_CC structural_JJ and_CC nonstructural_JJ portions_NNS of_II HCV_NN ._.
P07529954A02
STUDY_NN DESIGN_NN AND_CC METHODS_NNS :_: Thirty-nine_MC anti-HCV-positive_JJ donors_NNS with_II normal_JJ ALT_NN on_II four_MC determinations_NNS at_II 3-month_NN intervals_NNS were_VBD further_RR tested_VVN monthly_RR for_II 6_MC months_NNS ,_, and_CC they_PN had_VHD normal_JJ ALT_NN values_NNS ._.
P07531753A05
Fifteen_MC of_II the_DD 33_MC (_( 45.5_MC %_SYM )_) anti-HCV_NN positive_JJ patients_NNS had_VHD HCV_NN RNA_NN in_II the_DD serum_NN ._.
P07532341A03
Viraemia_NN was_VBD revealed_VVN by_II polymerase_NN chain_NN reaction_NN in_II all_DD group_NN 1_MC cases_NNS ._.
P07535737A06
Three_MC of_II the_DD HCV_NN RNA-positive_JJ and_CC none_MC of_II the_DD HCV_NN RNA-negative_JJ subjects_NNS had_VHD chronic_JJ hepatitis_NN ._.
P07539831A02
Patients_NNS were_VBD placed_VVN into_II three_MC different_JJ groups_NNS :_: 1_MC )_) patients_NNS ever_RR treated_VVN with_II large_JJ pool_NN non-hepatitis_NN C_NN virus_NN (_( HCV_NN )_) -safe_JJ concentrate_NN (_( n_NN =_SYM 179_MC )_) ;_: 2_MC )_) patients_NNS treated_VVN with_II cryoprecipitate_NN (_( n_NN =_SYM 125_MC )_) ;_: and_CC 3_MC )_) patients_NNS treated_VVN exclusively_RR with_II HCV-save_JJ concentrate_NN (_( n_NN =_SYM 12_MC )_) ._.
P07540080A07
HCV-RNA_NN was_VBD detected_VVN in_II 5_MC of_II 22_MC infants_NNS in_II the_DD fourth_JJ month_NN ._.
P07545210A09
However_RR ,_, there_EX was_VBD no_DD difference_NN in_II alanine_NN transaminase_NN (_( ALT_NN )_) levels_NNS ,_, histological_JJ lesions_NNS ,_, and_CC RIBA-2_NN patterns_NNS in_II blood_NN donors_NNS infected_VVN with_II either_CC HCV_NN genotype_NN I_MC or_CC HCV_NN genotype_NN II_MC ._.
P07554533A07
There_EX was_VBD a_DD good_JJ association_NN between_II serum_NN HCV_NN RNA_NN and_CC circulating_VVGJ anti-HCV_NN antibodies_NNS ,_, tested_VVN by_II second-generation_NN ELISA_NN and_CC RIBA_NN assays_NNS ._.
P07678638A01
Serum_NN samples_NNS from_II 103_MC blood_NN donors_NNS or_CC patients_NNS with_II slightly_RR increased_VVNJ serum_NN levels_NNS of_II liver_NN enzymes_NNS were_VBD tested_VVN for_II antibodies_NNS to_II hepatitis_NN C_NN virus_NN (_( anti-HCV_NN )_) using_VVG second_JJ generation_NN tests_NNS and_CC for_II HCV_NN RNA_NN by_II the_DD polymerase_NN chain_NN reaction_NN (_( PCR_NN )_) ._.
P07684749A04
The_DD prevalence_NN of_II HCV_NN viremia_NN ranged_VVD from_II 25.9_MC %_SYM in_II HCV_NN antibody-positive_JJ blood_NN donors_NNS to_II 92_MC %_SYM in_II HCV_NN antibody-positive_JJ hemophiliacs_NNS ._.
P07685969A04
Five_MC of_II the_DD 7_MC EIA-2-positive_JJ donors_NNS had_VHD detectable_JJ HCV_NN RNA_NN ._.
P07686741A05
During_II the_DD follow-up_NN period_NN (_( >_SYM or_CC =_SYM 6_MC months_NNS )_) ,_, acute_JJ non-A_NN ,_, non-B_NN hepatitis_NN developed_VVD in_II three_MC of_II 90_MC recipients_NNS about_RR 1_MC month_NN after_II the_DD accident_NN ._.
P07798884A01
Hepatitis_NN C_NN virus_NN (_( HCV_NN )_) is_VBZ transmitted_VVD by_II organs_NNS of_II HCV_NN antibody-positive_JJ donors_NNS to_II transplant_NN recipients_NNS ._.
P07843701A05
Clearance_NN of_II passively_RR acquired_VVNJ anti-HCV_NN antibodies_NNS was_VBD found_VVN to_TO be_VBI slower_JJR among_II babies_NNS born_VVN to_II HIV+_NN mothers_NNS (_( 22.3_MC %_SYM vs._CC 3.8_MC %_SYM at_II 12_MC months_NNS ,_, P_NN =_SYM .03_MC )_) and_CC children_NNS whose_PNR mothers_NNS showed_VVD three_MC or_CC four_MC anti-HCV_NN reactivities_NNS by_II immunoblotting_VVGN maintained_VVD anti-HCV_NN for_II longer_JJR periods_NNS compared_VVN with_II babies_NNS born_VVN to_II mothers_NNS with_II one_MC or_CC two_MC anti-HCV_NN reactivities_NNS (_( P_NN =_SYM .0001_MC )_) ._.
P07924751A03
We_PN therefore_RR performed_VVD a_DD cross-sectional_JJ study_NN to_TO determine_VVI the_DD prevalence_NN of_II HCV_NN infection_NN in_II children_NNS who_PNR had_VHD undergone_VVN liver_NN transplantation_NN ._.
P07971011A06
In_II Group_NN C_NN ,_, all_DD 13_MC patients_NNS had_VHD detectable_JJ HCV_NN RNA_NN in_II serum_NN ._.
P08023395A09
CONCLUSION_NN :_: These_DD data_NNS confirm_VVB a_DD good_JJ correlation_NN between_II RIBA-2_NN reactivity_NN and_CC the_DD detection_NN of_II HCV_NN RNA_NN in_II a_DD population_NN of_II anti-HCV-positive_JJ blood_NN donors_NNS ._.
P08042947A09
Of_II the_DD remaining_VVGJ subjects_NNS (_( seven_MC /_SYM 36_MC )_) who_PNR were_VBD anti-HCV-negative_JJ ,_, three_MC /_SYM seven_MC were_VBD HCV-RNA-positive_JJ and_CC included_VVD two_MC with_II acute_JJ post-transfusion_NN (_( PT_NN )_) NANBH_NN and_CC a_DD recent_JJ needlestick_NN victim_NN who_PNR contracted_VVD HCV_NN ._.
P08166987A01
HCV_NN infection_NN causes_VVZ serious_JJ complications_NNS in_II dialysis_NN patients_NNS that_PNR lead_VVB to_II problems_NNS in_II management_NN of_II patients_NNS in_II dialysis_NN units_NNS ._.
P08261814A05
Ten_MC ELISA2-positive_JJ women_NNS had_VHD a_DD further_JJ evaluation_NN with_II assessment_NN of_II HCV_NN infection_NN in_II their_PNG children_NNS ._.
P08264141A07
Anti-HCV_NN antibodies_NNS are_VBB frequently_RR associated_VVN with_II HCV_NN viremia_NN ,_, resulting_VVG usually_RR in_II chronic_JJ hepatitis_NN ,_, although_CS hypertransaminasemia_NN is_VBZ uncommon_JJ ._.
P08381269A09
Based_VVN on_II these_DD data_NNS ,_, we_PN anticipate_VVB that_CST screening_VVGN by_II anti-C100-3_NN in_II Taiwan_NNP will_VM exclude_VVB approximately_RR 3280_MC potentially_RR infectious_JJ donations_NNS under_II the_DD current_JJ screening_VVGJ policy_NN but_CC will_VM result_VVB in_II the_DD loss_NN of_II 6860_MC donations_NNS that_PNR will_VM be_VBB negative_JJ for_II HCV_NN RNA_NN per_II year_NN ._.
P08387411A06
Our_PNG sensitive_JJ and_CC specific_JJ PCR_NN assay_NN was_VBD unable_JJ to_TO detect_VVI HCV_NN RNA_NN in_II the_DD six_MC preparations_NNS tested_VVN ._.
P08588133A05
Of_II these_PND 11_MC were_VBD previously_RR undiagnosed_VVN ,_, and_CC seven_MC were_VBD HCV_NN RNA-positive_JJ ._.
P08637513A04
The_DD evaluations_NNS also_RR included_VVD an_DD assessment_NN of_II risk_NN factors_NNS ,_, a_DD physical_JJ examination_NN ,_, serial_JJ determinations_NNS of_II alanine_NN aminotransferase_NN levels_NNS and_CC HCV_NN serologic_JJ assays_NNS ,_, a_DD polymerase-chain-reaction_NN assay_NN for_II HCV_NN RNA_NN ,_, testing_VVGN of_II sexual_JJ contacts_NNS and_CC family_NN members_NNS ,_, and_CC liver_NN biopsies_NNS in_II some_DD participants_NNS who_PNR were_VBD HCV-positive_JJ by_II RIBA_NN ._.
P08649626A14
CONCLUSIONS_NNS ._.
P08748278A08
The_DD distribution_NN of_II HCV_NN genotypes_NNS did_VDD not_RR differ_VVB significantly_RR between_II HCV_NN RNA-positive_JJ patients_NNS with_II indeterminate_JJ or_CC positive_JJ RIBA3.0_NN results_NNS ._.
P08779139A08
In_II the_DD blood_NN donor_NN control_NN group_NN the_DD prevalence_NN of_II HCV_NN antibodies_NNS was_VBD lower_JJR (_( 0.3_MC %_SYM )_) ._.
P08784559A01
The_DD prevalence_NN of_II hepatitis_NN C_NN virus_NN (_( HCV_NN )_) infection_NN was_VBD evaluated_VVN in_II 227_MC hemodialysis_NN patients_NNS from_II four_MC units_NNS in_II Caracas_NNP ,_, Venezuela_NNP ,_, by_II using_VVGN different_JJ second-_JJ and_CC third-generation_NN enzyme_NN immunoassays_NNS (_( EIAs_NNS )_) and_CC immunoblot_NN assays_NNS ._.
P08793841A07
A_DD clear_JJ association_NN was_VBD observed_VVN between_II HCV-RNAemia_NN in_II serum_NN samples_NNS and_CC index_NN values_NNS (_( O.D._NN sample_NN /_SYM O.D._NN cut-off_NN )_) of_II the_DD screening_VVGJ EIAs_NNS as_CC+ well_CC+ as_CC with_II the_DD number_NN of_II reactive_JJ proteins_NNS in_II the_DD confirmatory_JJ assays_NNS ._.
P08818962A02
Sixteen_MC of_II 200_MC (_( 8_MC %_SYM )_) donors_NNS were_VBD positive_JJ for_II antibodies_NNS using_VVG a_DD second_JJ generation_NN enzyme-linked_VVNJ immunosorbent_JJ assay_NN (_( ELISA_NN )_) but_CC all_PND of_II the_DD children_NNS were_VBD negative_JJ ._.
P08818968A11
This_DD information_NN appears_VVZ useful_JJ for_II establishing_VVGN criteria_NNS in_II future_JJ screening_VVGJ policies_NNS ._.
P08822625A09
This_DD situation_NN was_VBD particularly_RR evidenced_VVN in_II selected_VVNJ sera_NNS from_II poor_JJ responder_NN specimens_NNS where_PNR a_DD more_RR restricted_VVNJ antibody_NN response_NN to_II core_NN peptides_NNS was_VBD observed_VVN ._.
P08837233A03
However_RR ,_, haemodialysis_NN patients_NNS and_CC haemophiliacs_NNS were_VBD at_II higher_JJR risk_NN of_II having_VVGN HCV_NN infection_NN ,_, since_CS the_DD prevalences_NNS were_VBD ,_, respectively_RR ,_, 35.1_MC and_CC 42.4_MC %_SYM in_II comparison_NN with_II the_DD blood_NN donors_NNS '_GE prevalence_NN (_( 1.1_MC %_SYM )_) ._.
P08871873A04
In_II those_PND with_II ALD_NN ,_, anti-HCV_NN and_CC HCV_NN RNA_NN were_VBD positive_JJ in_II 55.5_MC %_SYM and_CC 41.2_MC %_SYM ,_, respectively_RR ._.
P08888703A13
Chronic_JJ hepatitis_NN was_VBD diagnosed_VVN in_II 88_MC %_SYM vs_CC 43_MC %_SYM of_II donors_NNS with_II elevated_VVNJ and_CC normal_JJ alanine_NN aminotransferase_NN levels_NNS ,_, respectively_RR ._.
P08941587A06
Risk_NN factors_NNS including_VVG blood_NN transfusions_NNS were_VBD evaluated_VVN ._.
P08968936A03
This_DD study_NN was_VBD performed_VVN to_TO establish_VVI the_DD significance_NN of_II indeterminate_JJ RIBA_NN 2.0_MC results_NNS in_II relation_NN to_II HCV_NN RNA_NN detection_NN ,_, high_JJ positivity_NN for_II the_DD c22-3_NN band_NN ,_, and_CC the_DD HCV_NN genotype_NN as_CS determined_VVN by_II direct_JJ DNA_NN sequencing_VVGN ._.
P08986942A05
Sera_NNS from_II only_RR two_MC (_( 3.4_MC %_SYM )_) of_II the_DD 59_MC anti-HCV_NN negative_JJ ,_, HCV_NN RNA_NN positive_JJ patients_NNS recognised_VVD sE2_NN and_CC none_MC dE2_NN ._.
P08995939A05
RESULTS_NNS :_: Of_II 114_MC patients_NNS who_PNR were_VBD treated_VVN with_II IFN-alpha_NN for_II 24_MC weeks_NNS ,_, 22_MC of_II 29_MC patients_NNS (_( 75.9_MC %_SYM )_) who_PNR lost_VVD HCV_NN RNA_NN at_II the_DD first_JJ week_NN of_II treatment_NN ,_, 5_MC of_II 14_MC patients_NNS (_( 35.7_MC %_SYM )_) who_PNR lost_VVD HCV_NN RNA_NN at_II the_DD second_JJ week_NN ,_, and_CC 2_MC of_II 16_MC patients_NNS (_( 12.5_MC %_SYM )_) who_PNR lost_VVD HCV_NN RNA_NN at_II fourth_JJ week_NN were_VBD judged_VVN as_II sustained_VVNJ responder_NN (_( SR_NN )_) ._.
P09076628A06
Both_CC HCV-2_NN and_CC E2_NN /_SYM NS1_NN antibodies_NNS were_VBD positive_JJ at_RR+ least_RR once_NN in_II all_DD patients_NNS ._.
P09242566A05
Five_MC ID_NN patients_NNS never_RR developed_VVD HCV_NN antibodies_NNS despite_II serum_NN HCV-RNA_NN positivity_NN ._.
P09252071A06
No_DD other_JJ significant_JJ difference_NN was_VBD observed_VVN in_II any_PND of_II the_DD patients_NNS '_GE characteristics_NNS between_II IgM_NN anti-HCV_NN core_NN positive_JJ and_CC negative_JJ groups_NNS ._.
P09430360A01
The_DD risk_NN of_II perinatal_JJ transmission_NN of_II hepatitis_NN C_NN virus_NN (_( HCV_NN )_) from_II a_DD cohort_NN of_II 95_MC human_NN immunodeficiency_NN virus_NN (_( HIV_NN )_) -negative_JJ intravenous_JJ drug_NN users_NNS (_( IVDU_NN )_) is_VBZ described_VVN ,_, 89_MC of_II whom_PNR were_VBD positive_JJ for_II antibodies_NNS to_II HCV_NN (_( anti-HCV_NN )_) ._.
P09438545A01
The_DD immunoreactivity_NN profiles_NNS of_II plasma_NN samples_NNS obtained_VVN from_II patients_NNS infected_VVN with_II different_JJ hepatitis_NN C_NN virus_NN (_( HCV_NN )_) genotypes_NNS were_VBD studied_VVN using_VVG immunoblot_NN assay_NN containing_VVG multiple_JJ HCV_NN antigens_NNS ._.
P09504268A04
MATERIALS_NNS :_: From_II May_NN 1991_MC to_II August_NN 1996_MC more_RR than_CSN 4300_MC patients_NNS were_VBD tested_VVN for_II anti-HCV_NN ._.
P09592344A10
These_DD data_NNS indicate_VVB that_CST many_DD patients_NNS on_II hemodialysis_NN have_VHB hepatitis_NN C_NN or_CC B_NN viremia_NN and_CC more_DD attention_NN should_VM be_VBB paid_VVN to_II this_DD problem_NN ._.
P09619970A01
Serum_NN hepatitis_NN C_NN virus_NN (_( HCV_NN )_) RNA_NN ,_, HCV_NN genotypes_NNS and_CC liver_NN function_NN tests_NNS were_VBD evaluated_VVN in_II a_DD series_NN of_II 189_MC unselected_VVNJ ,_, consecutive_JJ anti-HCV_NN positive_JJ intravenous_JJ drug_NN users_NNS (_( IVDUs_NNS )_) ._.
P09620405A01
A_DD national_JJ survey_NN of_II hepatitis_NN C_NN virus_NN (_( HCV_NN )_) infections_NNS among_II dialysis_NN patients_NNS in_II The_DD Netherlands_NNP was_VBD performed_VVN ._.
P09620405A15
The_DD prevalence_NN of_II HCV-infected_VVNJ patients_NNS in_II Dutch_NN dialysis_NN centers_NNS ranged_VVD from_II 0_MC to_II 8_MC %_SYM ,_, suggesting_VVG the_DD existence_NN of_II local_JJ risk_NN factors_NNS for_II acquiring_VVGN HCV_NN infection_NN ._.
P09665375A08
Of_II these_PND ,_, 1_MC was_VBD RIBA_NN 2.0_MC negative_JJ (_( PCR_NN positive_JJ )_) ,_, 3_MC were_VBD indeterminate_JJ (_( 3_MC PCR_NN positive_JJ )_) ,_, and_CC 28_MC were_VBD positive_JJ (_( 23_MC PCR_NN positive_JJ )_) ._.
P09681732A02
Some_DD HD_NN patients_NNS may_VM have_VHB ,_, therefore_RR ,_, an_DD inability_NN to_TO produce_VVI detectable_JJ amounts_NNS of_II serum_NN antibodies_NNS to_II hepatitis_NN C_NN virus_NN (_( anti-HCV_NN )_) ._.
P09809407A10
High_JJ percentages_NNS of_II PCR_NN positive_JJ results_NNS among_II RIBA-3-indeterminate_JJ and_CC among_II MATRIX-indeterminate_JJ samples_NNS indicate_VVB an_DD increased_VVNJ possibility_NN of_II detecting_VVGN HCV_NN RNA_NN if_CS at_RR+ least_RR one_MC antigen_NN is_VBZ reactive_JJ ._.
P09881424A13
In_II many_DD instances_NNS there_EX was_VBD more_RR than_CSN one_MC recipient_NN per_II HCV_NN infected_VVNJ donation_NN ._.
P10068359A07
RESULTS_NNS :_: Ten_MC cases_NNS of_II infection_NN with_II acute_JJ HCV_NN genotype_NN 3a_NN occurred_VVD between_II 1990_MC and_CC 1993_MC ._.
P10094968A02
We_PN examined_VVD the_DD results_NNS of_II laboratory_NN tests_NNS for_II HCV_NN on_II a_DD cohort_NN of_II patients_NNS who_PNR received_VVD a_DD liver_NN transplant_NN between_II 1990_MC and_CC 1994_MC at_II three_MC large_JJ centers_NNS ._.
P10220737A04
Age_NN was_VBD the_DD most_RRT potential_JJ risk_NN indicator_NN for_II anti-HCV_NN positivity_NN by_II multiple_JJ stepwise_JJ regression_NN analysis_NN ._.
P10331562A08
Monitoring_VVGN anti-Core_NN 518_MC titers_NNS may_VM be_VBB helpful_JJ not_RR only_RR for_II differentiating_VVGN the_DD status_NN of_II HCV_NN infection_NN among_II patients_NNS with_II various_JJ type_NN C_NN viral_JJ liver_NN diseases_NNS ,_, but_CC also_RR for_II predicting_VVGN responses_NNS to_II IFN-alpha_NN treatment_NN ._.
P10374301A09
HCV_NN infection_NN rate_NN in_II hemodialysis_NN patients_NNS is_VBZ higher_JJR than_CSN that_PND of_II general_JJ population_NN ._.
P10438705A13
In_II all_DD 5_MC individuals_NNS ,_, independent_JJ repeats_NNS of_II the_DD experiments_NNS confirmed_VVD the_DD presence_NN of_II HCV_NN RNA_NN in_II serum_NN ,_, and_CC in_II 3_MC of_II these_DD individuals_NNS ,_, HCV-positivity_NN was_VBD confirmed_VVN in_II independently_RR collected_VVNJ plasma_NN and_CC PBMC_NN samples_NNS ._.
P10507992A02
The_DD prevalence_NN of_II anti-HCV_NN antibodies_NNS was_VBD 3.2_MC %_SYM (_( 26_MC /_SYM 820_MC )_) among_II blood_NN donors_NNS in_II Khon_NNP Kaen_NNP ,_, while_CS it_PN was_VBD 90_MC %_SYM (_( 71_MC /_SYM 79_MC )_) among_II IVDUs_NNS in_II Chiang_NNP Rai_NNP ._.
P10533794A11
Twenty-three_MC patients_NNS with_II chronic_JJ active_JJ hepatitis_NN were_VBD treated_VVN with_II interferon-alpha_NN ._.
P10534725A10
In_II some_DD patients_NNS infected_VVN with_II two_MC genotypes_NNS ,_, the_DD spontaneous_JJ loss_NN of_II the_DD 3a_NN genotype_NN was_VBD observed_VVN ._.
P10624011A02
Sex_NN ,_, age_NN ,_, duration_NN of_II dialysis_NN ,_, number_NN of_II transfusions_NNS and_CC ALT_NN were_VBD also_RR considered_VVN ._.
P10669321A06
Mean_NN ALT_NN concentrations_NNS decreased_VVD substantially_RR after_II the_DD first_JJ 2_MC years_NNS of_II life_NN ;_: 14_MC children_NNS had_VHD persistently_RR normal_JJ ALT_NN values_NNS ._.
P11059937A07
Hepatitis_NN C_NN virus-RNA_NN was_VBD detected_VVN in_II 78_MC %_SYM of_II the_DD HCV_NN antibody-positive_JJ cases_NNS ._.
P11163587A14
Nosocomial_JJ infections_NNS and_CC tattooing_VVGN were_VBD found_VVN to_TO be_VBI the_DD most_RRT important_JJ risk_NN factors_NNS for_II transmission_NN of_II HCV_NN ._.
P11179591A08
RESULTS_NNS :_: The_DD presence_NN of_II anti-HCV_NN IgG_NN was_VBD detected_VVN in_II a_DD total_NN of_II 48_MC cases_NNS (_( 1.9_MC %_SYM )_) ._.
P11189001A03
This_DD study_NN aims_VVZ to_TO investigate_VVI such_DD correlation_NN and_CC to_TO provide_VVI further_JJ evidence_NN to_II the_DD possible_JJ transmissibility_NN of_II HCV_NN via_II corneal_JJ grafts_NNS ._.
P11268963A04
The_DD relatives_NNS were_VBD 45_MC spouses_NNS ,_, 89_MC children_NNS and_CC 4_MC cohabitants_NNS who_PNR underwent_VVD detection_NN of_II serum_NN anti-HCV_NN antibodies_NNS ;_: the_DD anti-HCV-positive_JJ subjects_NNS were_VBD tested_VVN for_II serum_NN HCV-RNA_NN ._.
P11274586A08
RESULTS_NNS :_: Three_MC donations_NNS out_II+ of_II 251,737_MC were_VBD HCV_NN RNA_NN positive_JJ and_CC anti-HCV_NN negative_JJ ._.
P11318976A15
The_DD occurrence_NN of_II the_DD lesions_NNS after_II the_DD appearance_NN of_II anti-HCV_NN antibodies_NNS and_CC the_DD high_JJ HCV_NN RNA_NN levels_NNS are_VBB indicative_JJ of_II viral_JJ involvement_NN in_II the_DD pathogenesis_NN ._.
P11421370A09
Those_PND who_PNR were_VBD less_RR educated_VVN ,_, farmed_VVD ,_, provided_VVD health_NN care_NN ,_, and_CC were_VBD currently_RR married_VVN had_VHD a_DD significantly_RR higher_JJR anti-HCV_NN prevalence_NN than_CSN those_PND who_PNR were_VBD not_RR ;_: however_RR ,_, these_DD associations_NNS were_VBD not_RR significant_JJ after_II adjusting_VVGN for_II age_NN ._.